Newsroom.

GC Biopharma Initiates Voluntary Market Withdrawal of One Lot of Product

GC Biopharma Supports New Insights into Education, Safety, and Patient Outcomes in Ig Therapy Care at the 2025 IgNS Annual Meeting

GC Biopharma Announces Symposium on Clinical and Patient Experience in Primary Immunodeficiency and Poster Presentations on IVIG Manufacturing and Viscosity at the 2025 IgNS Annual Meeting

GC Biopharma Highlights IVIG Innovation and Investigator-Initiated Research as Science to Solutions Partner at the Fall 2025 CIIC Conference

GC Biopharma Announces Publication Demonstrating 14-Day Stability of Pooled ALYGLO^® Under Refrigerated Conditions

GC Biopharma Presents New Viscosity Research on IVIG Products at ISTH 2025

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

GC Biopharma Acquires ABO Holdings to Boost U.S. Blood Products Business ABO Holdings, based in California, Operates 6 Blood Banks in the U.S.

GC Biopharma Showcases ALYGLO^® at IGNS Conference: Advancing the IVIG process with CEX Chromatography

GC Biopharma Presents Poster Abstract on Cation Exchange Chromatography at NASP 2024

Sean Zam named Head of Sales and Marketing at GC Biopharma USA

Christina Iskandar has been appointed Associate Director of Human Resources at GC Biopharma USA

GC Biopharma Launches ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults, an Immune Globulin for the Treatment of Primary Humoral Immunodeficiency (PI) - Now Available in the US Marketplace

GC Biopharma USA Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

GC Biopharma USA Announces Publication Describing Proprietary Cation Exchange Chromatography (CEX) Removing FXIa from a 10% Intravenous Immunoglobulin (GC5107) Preparation

GC Biopharma US Team to Present Clinical Symposium on GC Biopharma's patented CEX Technology Manufacturing Process at IgNS 2023 Annual Conference

US FDA Accepts Biologics License Application for GC Biopharma’s GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

GC Biopharma US Team to Present Poster at IgNS 2022 Annual Conference

GC Biopharma and Speragen Sponsored an Externally Led - Patient-Focused Drug Development

GC Signs Definitive Agreement to Acquire US CDMO BioCentriq, Enhancing Global Capabilities

GC Biopharma Announces Publication of Results from Phase III Clinical Trial of 'GC5107' Immune Globulin in Frontiers in Immunology

US FDA Accepts GC Biopharma's Biologics License Application for Immune Globulin 'GC5107'

GC Biopharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

GC Biopharma Appoints New CEO and Head of Finance and Operations to GC Biopharma USA, Inc. Executive Leadership Team

GC Strategically Divests Certain Assets in North American Business

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

Clinical Immunology Society (CIS) Accepts GC Biopharma USA, Inc.’s Abstract for Poster Presentation at Their National Conference

GC Biopharma Launches Project to Develop CoVid-19 Vaccine and Treatment in South Korea With Support From the Korea Center for Disease Control

GC Biopharma USA, Inc. Supports and Participates in Soleo Health National Sales Meeting in Austin, Texas

GCAM, the Us Based Plasma Collection Division of GC Biopharma, Opens a New Collection Center in Texas

GC Biopharma USA, Inc. Presents Poster at IgNS National Conference

GCAM Hosts Opening Ceremony for New Plasma Center in Brownsville, TX

Curevo, Seattle-Based Biotech Company Owned by GC Biopharma Announces FDA Advancement of IND Application for CRV-101, the New Shingles Candidate

GC Biopharma USA, Inc. Finishes the Completion of the US Corporate Headquarters in Fort Lee, NJ